The "INOmax 2016 U.S Promotional Report" report has been added to Research and Markets' offering.
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by INOmax through personal promotion in 2016 to drive use within the Hypoxic Respiratory Failure?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does Mallinckrodt's depth of coverage vary within key specialties (e.g., Pediatric Medicine) and how does this compare to the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for INOmax throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers for INOmax in 2016?
Data Sources and Methodology:
- We leverage company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available - covering payments to more than 900,000 U.S. healthcare professionals.
- Over 700 paid interactions across 400 physicians made on behalf of INOmax were carefully examined to support our analysis.
For more information about this report visit https://www.researchandmarkets.com/research/h6btfw/u_s_inomax?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005454/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Respiratory
Drugs